New Options for Treatment-Resistant CML & One Type of ALL

New Options for Treatment-Resistant CML & One Type of ALL

9108605_s

 

The drug Gleevac has been hailed as a life saving treatment for certain types of leukemia.  However, just as no two people are alike, no two cancers are exactly alike.  For some people, their cancer is resistant to certain treatments.

 

Good news though… The FDA has recently approved 3 new treatment options for patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+) whose disease is resistant or intolerant to Gleevac.

 

For these patients, newly approved ponatinib (Iclusig), bosutinib (Bosulif) and omacetaxine (Synribo) offer hope as an effective treatment option.  These new drugs work by thwarting treatment-resistant mutations (ponatinib and bosutinib) or by stifling creation of an aberrant protein (omacetaxine).

 

For more information on these drugs, their contraindications, or assistance in paying for them, check out Chemo101.  If you’ve been diagnosed with chronic myeloid leukemia (CML), check out the National CML Society, an incredible, one-stop resource for anything & everything related to CML.  Knowledge is power…

 

 

 

 

 



At the CancerHawk Foundation, our mission is to make the services, products and expertise needed to fight cancer sharply visible to patients and caregivers. Get the latest news, information and resources to help you navigate your way through the complexities of cancer by subscribing to our most important updates in the right hand sidebar.

We also invite you to like, share, tweet and comment on this post.

Leave a Reply

Your email address will not be published. Required fields are marked *



Get the latest news, information and resources to help you navigate your way through the complexities of cancer.